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Background
Zealand Pharma has invented a glucagon analogue, ZP-GA-1, 
with increased stability in liquid formulation for treatment of 
hypoglycemia. A pharmacodynamic (PD) model is needed to 
compare ZP-GA-1 with marketed glucagon. We aim to develop 
a model of the complex glucose-insulin-glucagon dynamics 
based on physiology and data.
Discussion
Profile likelihood analysis revealed that some model para-
meters were unidentifiable (dark grey) due to limitations in the 
dynamics of the datasets. Model parameters describing the 
glucose response due to glucagon at concentrations below 
saturation (E0, EC50, γ) could not be estimated from the 
datasets since plasma glucagon concentrations were high 
during the entire sampling period.
Zealand’s novel glucagon analogue, ZP-GA-1, shows PD 
characteristics similar to marketed glucagon.
The new model enables simulations of the glucose-insulin-
glucagon dynamics. 
Methods
Five dogs were included in a randomized cross-over study. At 
four dosing occasions each dog received a SC bolus injection 
of 20 or 120 nmol/kg glucagon (GlucaGen ®) or ZP-GA-1. 
Blood samples were collected at 0, 5, 10, 15, 20, 30, 40, 50, 60, 
75, 110, 140, and 180 minutes after dose administration. 
We adopted a physiological model of endogenous glucose 
production with multiplicative effects of insulin and glucagon 
and combined it with the Hovorka model of glucose and 
insulin. The model was fitted to each individual dataset by 
Maximum a Posteriori (MAP) estimation of model parameters 
given priors reported in literature using the CTSM package in 
R (version 3.1.0). Profile likelihood analysis was used to fixate 
unidentifiable parameters at prior mean values.
Glucagon ZP-GA-1 P-value
E0 (μmol/kg/min) 8 -
Emax (μmol/kg/min) (50.1, 13.7) (53.8, 16.5) 0.51
EC50 (pg/mL) 337.8 -
γ (-) 1 -
F01 (μmol/kg/min) (9.8, 1.5) (9.6, 2.0) 0.81
Log-distributions
k12 (1/min) (-2.87, 0.27) (-3.02, 0.23) 0.29
ka1 (1/min) (-5.19, 0.86) (-5.90, 0.83) 0.09
ka2 (1/min) -2.89 -
ka3 (1/min) (-4.88, 0.73) (-4.70, 0.98) 0.42
SD (L/mIU/min) (-9.11, 0.93) (-8.72, 1.15) 0.42
SE (L/mIU) (-2.71, 0.57) (-2.95, 0.43) 0.14
ST (L/mIU/min) (-5.65, 0.86) (-5.35, 0.50) 0.19
Figure 2: PK profiles and PD responses after a bolus of glucagon (left) or 
ZP-GA-1 (right) in one dog. Fit and 95% confidence limits are shown. 
Figure 1: Diagram of the PD model with glucagon or analogue (C), and 
insulin (I) concentrations as inputs and glucose (G) concentration as 
output.
ConclusionsResults
For each identifiable model parameter, posterior probability 
distributions (teal and blue) are listed along with p-values (red) 
of two-tailed paired t-tests comparing glucagon and ZP-GA-1 
model parameter values.
